European pharmaceuticals group Sanofi on Tuesday said its application for review for its new drug, lixisenatide, a diabetes treatment, had been accepted by the U.S. Food and Drug Administration.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2015-09-29 01:14:042015-09-29 13:06:24Sanofi says application for new diabetes drug under FDA review
Zosano Terminates Eli Lilly Deal, Halts Daily Osteoporosis Drug Program